Risk assessment for transmission of variant Creutzfeldt-Jakob disease by transfusion of red blood cells in the United States

Transfusion

Volumn 54, Issue 9, 2014, Pages 2194-2201

  Yang, Hong ^a   Gregori, Luisa ^a   Asher, David M ^a   Epstein, Jay S ^a   Anderson, Steven A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BOVINE SPONGIFORM ENCEPHALOPATHY AGENT; CHILD; CONTROLLED STUDY; DISEASE TRANSMISSION; ERYTHROCYTE TRANSFUSION; EUROPE; HUMAN; INCUBATION TIME; MAJOR CLINICAL STUDY; PREVALENCE; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; UNITED KINGDOM; UNITED STATES; VARIANT CREUTZFELDT JAKOB DISEASE; VARIANT CREUTZFELDT JAKOB DISEASE AGENT; ANIMAL; BOVINAE; CREUTZFELDT-JAKOB SYNDROME; ENCEPHALOPATHY, BOVINE SPONGIFORM; THEORETICAL MODEL; TRANSMISSION;

ANIMALS; CATTLE; CREUTZFELDT-JAKOB SYNDROME; ENCEPHALOPATHY, BOVINE SPONGIFORM; ERYTHROCYTE TRANSFUSION; GREAT BRITAIN; HUMANS; MODELS, THEORETICAL; RISK ASSESSMENT; UNITED STATES;

EID: 84908210595     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12637     Document Type: Article

References (33)

1. Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997;389:448-50.
2. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent. Nature 1997;389:498-501.
3. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363:417-21.
4. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004;364:527-9.
5. Editorial Team. New case of transfusion-associated variant-CJD in the United Kingdom. Eurosurveillance 2006;11:pii=2895.
6. Editorial Team. Fourth case of transfusion-associated variant-CJD infection in the United Kingdom. Eurosurveillance 2007;12:pii=3117.
7. Food and Drug Administration. Guidance for industry revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products. May 2010 [cited 2014 Mar 19]. Available from: http://www.fda.gov/downloads/BiologicsBlood Vaccines/GuidanceComplianceRegulatoryInformation/ Guidances/UCM213415.pdf
8. USDA. BSE Ongoing surveillance program. Bovine spongiform encephalopathy (BSE). [cited 2014 Mar 19]. Available from: http://usda.gov/wps/portal/usda/usdahome? contentid=BSE-Ongoing-Surveillance-Information-Center.html
9. OIE. 81st General Session of theWorld Assembly of Delegates. May 2013. [cited 2013 Sep 6]. Available from: http://www.oie.int/for-the-media/press-releases/detail/ article/81st-general-session-of-the-world-assembly-of-delegates-of-the-world-organisation-for-animal-health
10. Food and Drug Administration. A 2010 update of draft quantitative risk assessment of vCJD risk potentially associated with the use of human plasma-derived Factor VIII manufactured under United States (US) license from plasma collected in the US. 2010. [cited 2013 Sep 6]. Available from: http://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/ BloodVaccinesandOtherBiologics/Transmissible SpongiformEncephalopathiesAdvisoryCommittee/ ucm225805.htm
11. Garske T, Ghani AC. Uncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UK. Plos One 2010;5:e15626.
12. UK Health Protection Agency. Summary results of the second national survey of abnormal prion prevalence in archived appendix specimens. 2012 [cited 2013 Sep 6]. Available from: http://www.hpa.org.uk/hpr/archives/ 2012/news3212.htm#bnrmlprn
13. Gill ON, Spencer Y, Richard-Loendt A, et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ 2013;347:f5675.
14. Salmon R. How widespread is variant Creutzfeldt-Jakob disease? BMJ 2013;347:f5994.
15. Food and Drug Administration. TSEAC Meeting June 28, 2001. Transcripts pp. 24-51. AlanWilliams: Blood donor deferral options related to BSE exposure; risk reduction and estimated blood supply impact in the United States. [cited 2013 Sep 6]. Available from: http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3762t1-02.pdf
16. US Department of Health and Human Service. The 2007 national blood collection and utilization survey report. 2009. [cited 2013 Sep 6]. Available from: http://www.hhs.gov/ash/bloodsafety/nbcus/index.html
17. Forshee R, Walderhaug M. Who donates blood? Poster presented in 2009 Joint Statistical Meetings. August 1-6 2009,Washington, DC [cited 2013 Sep 6]. Available from: http://www.amstat.org/meetings/jsm/2009/onlineprogram/index.cfm?fuseaction=abstract-details&abstractid=304401
18. Collinge J. Cell biology. The risk of prion zoonoses. Science 2012;335:411-13.
19. Ghani AC, Donnelly CA, Ferguson NM, et al. Updated projections of future vCJD deaths in the UK. BMC Infect Dis 2003;3:4.
20. Belay ED, Sejvar JJ, Shieh WJ, et al. Variant Creutzfeldt-Jakob disease death, United States. Emerg Infect Dis 2005; 11:1351-4.
21. Kaski D, Mead S, Hyare H, et al. Variant CJD in an individual heterozygous for PRNP codon 129. Lancet 2009; 374:2128.
22. Houston F, McCutcheon S, Goldmann W, et al. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008;112:4739-45.
23. Alperovitch A, Zerr I, Pocchiari M, et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 1999;353:1673-74.
24. Food and Drug Administration. TSEAC meeting. October 31, 2005 meeting transcript. [cited 2013 Jan 24]. Available from: http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4189t1.htm
25. Food and Drug Administration. TSEAC. December 15, 2006 meeting transcript. [cited 2013 Jul 17]. Available from: http://www.fda.gov/ohrms/dockets/ac/06/ transcripts/2006-4271t1.pdf
26. Anderson SA, Menis M, O'Connell K, et al. Blood use by inpatient elderly population in the United States. Transfusion 2007;47:582-92.
27. Gregori L, Yang H, Anderson SA. Estimation of variant Creutzfeldt-Jakob disease infectivity titers in human blood. Transfusion 2011;51:2596-602.
28. Bennett P, Daraktchiev M. vCJD and transfusion of blood components: an updated risk assessment. February 14, 2013 [cited 2013 Sep 6]. Available from: https://www.gov.uk/government/publications/vcjd-and-transfusion-of-blood-components-updated-risk-assessment
29. Food and Drug Administration. Transmissible Spongiform Encephalopathies Advisory Committee (TSEAC) meeting. March 14 2013. Draft Quantitative risk assessment of vCJD risk potentially associated with the transfusion of red blood cells in the US [cited 2013 Sep 6]. Available from: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/ BloodVaccinesandOtherBiologics/Transmissible SpongiformEncephalopathiesAdvisoryCommittee/ UCM343264.pdf
30. CDC. vCJD cases reported in the US. 2013 [cited 2014 Mar 19]. Available from: http://www.cdc.gov/ncidod/dvrd/ vcjd/factsheet-nvcjd.htm#reported
31. Foster PR. Removal of TSE agents from blood products. Vox Sang 2004;87:7-10.
32. Flan B, Arrabal S. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal. Transfus Clin Biol 2007;14:51-62.
33. Clarke P, Will RG, Ghani AC. Is there the potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK? J R Soc Interface 2007;4:675-84.